When was QATCH Technologies founded?

QATCH Technologies was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is QATCH Technologies located?

QATCH Technologies is headquartered in Durham, United States.

How many employees does QATCH Technologies have?

As of Mar 31, 2026, the latest employee count at QATCH Technologies is 6.

Is QATCH Technologies a funded company?

QATCH Technologies is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 15, 2017.

When was the latest funding round of QATCH Technologies?

QATCH Technologies' latest funding was a $***** Grant (prize money) round on Mar 12, 2025, with participation from 1 investor.

Where does QATCH Technologies rank among its competitors?

QATCH Technologies ranks 41st amongst 98 active competitors, of which 7 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was MindBio Therapeutics, which secured an undisclosed amount in Apr, 2026.

Who are the top competitors of QATCH Technologies?

QATCH Technologies' top competitors include Celerion, Altasciences and MindBio Therapeutics. Among them, MindBio Therapeutics secured the most recent funding round in April, 2026.

QATCH Technologies - 2026 Company Profile, Funding & Competitors

Most viewed in 2019

QATCH Technologies is a funded company based in Durham (United States), founded in 2016. It operates as a CRO focused on providing early stage drug development services. QATCH Technologies has raised an undisclosed amount in funding. The company has 98 active competitors, including 7 funded and 23 that have exited. Its top competitors include companies like Celerion, Altasciences and MindBio Therapeutics.

Key Metrics

Founded Year

2016

Location

Durham, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Mar 12, 2025, $*****

Investors

America’s Seed Fund & 2 more

Ranked

41^st among 98 active competitors

Employee Count

6 as on Mar 31, 2026

Similar Companies

Celerion & 117 more

View QATCH Technologies' full profile

QATCH Technologies has raised funding over 6 rounds. Its first funding round was on Jun 15, 2017. Its latest funding round was a Grant (prize money) round on Mar 12, 2025 for $*****. 1 investor participated in its latest round. QATCH Technologies has 3 institutional investors.

Here is the list of recent funding rounds of QATCH Technologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 12, 2025	9043456	Grant (prize money)	4493660	3563960	5774449	8577505
Sep 15, 2023	3989245	Grant (prize money)	5033834	5424109	5808304	National Science Foundation
Feb 08, 2022	9357357	Grant (prize money)	3630891	3599103	3111083	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of QATCH Technologies's funding rounds and investors

QATCH Technologies' employee count trend

QATCH Technologies has 6 employees as of Mar 26. Here is QATCH Technologies's employee count trend over the years:

Employee count trend for QATCH Technologies

Uncover QATCH Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of QATCH Technologies include Celerion, Altasciences and MindBio Therapeutics. Here is the list of Top 10 competitors of QATCH Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Celerion 2010, Lincoln (United States), Acquired	Translational medicine experts accelerating drug development for global patient impact	-	Bain Capital Ventures, SV Health Investors ... & 3 others	54/100
2nd	Altasciences 2015, Laval (Canada), Acquired	Early phase CRO	-	Signet Healthcare Partners, Apollo Investment Corporation ... & 1 others	52/100
3rd	MindBio Therapeutics 2021, Melbourne (Australia), Public	Provider of phase I & II clinical trial services for mental health diseases	-	Blackhawk Growth Corp, Hardenbrook Group	48/100
4th	HMR London 1993, London (United Kingdom), Acquired	Provider of early phase clinical research services for drug development	-	EIC Fund, Europa	48/100
5th	AWAKN 2020, Portishead (United Kingdom), Acquired	CRO focused on early stage clinical trial research	-	Palo Santo, Iter Investments	47/100
6th	BioPharma Services 2006, Toronto (Canada), Acquired	Provider of early stage clinical trial services	-	-	46/100
7th	Ask Gene Pharma 2012, Camarillo (United States), Series A	Innovating cytokine prodrugs for safer, more effective oncology and autoimmune therapies	$20M	TF Capital, Qiming Venture Partners	43/100
8th	Avance Clinical 2018, Thebarton (Australia), Late Stage	Provider of clinical development services	-	Riverside, Genesis Capital	43/100
9th	Aditum Bio 2019, Oakland (United States), Unfunded	CRO focused on clinical trial on phase II studies	-	-	42/100
10th	iCardiac Technologies 2006, Rochester (United States), Acquired	Company offering core laboratory services mainly for cardiac safety testing and respiratory diseases	$4M	Stonehenge Growth Equity Partners, Topmark Partners ... & 4 others	41/100
41st	QATCH Technologies 2016, Durham (United States), Funding Raised	CRO focused on providing early stage drug development services	-	America’s Seed Fund, National Science Foundation ... & 1 others	26/100